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Summary
Current guidelines advocate using fixed-doses of oral vitamin K to reverse excessive anticoagulation in warfarinised patients who are either asymptomatic or have minor bleeds. Over-anticoagulated patients present with a wide range of International Normalised Ratio (INR) values and response to fixed doses of vitamin K varies. Consequently a significant proportion of patients remain outside their target INR after vitamin K administration, making them prone to either haemorrhage or thromboembolism. We compared the performance of a novel tailored vitamin K dosing regimen to that of a fixed-dose regimen with the primary measure being the proportion of over-anticoagulated patients returning to their target INR within 24 h. One hundred and eighty-one patients with an index INR > 6Á0 (asymptomatic or with minor bleeding) were randomly allocated to receive oral administration of either a tailored dose (based upon index INR and body surface area) or a fixed-dose (1 or 2 mg) of vitamin K. A greater proportion of patients treated with the tailored dose returned to within target INR range compared to the fixed-dose regimen (68Á9% vs. 52Á8%; P = 0Á026), whilst a smaller proportion of patients remained above target INR range (12Á2% vs. 34Á0%; P < 0Á001). Individualised vitamin K dosing is more accurate than fixed-dose regimen in lowering INR to within target range in excessively anticoagulated patients.
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Despite improvements in the management of warfarin therapy, 50% of patients fail to stabilise within their target International Normalised Ratio (INR) range and are thus prone to the drug's adverse effect of bleeding ). Subgroup analyses of several studies show a sharp increase in the risk of bleeding when the INR exceeds the therapeutic range and increased risk of thrombosis when the INR falls below it (Fihn et al, 1996; The Stroke Prevention in Atrial Fibrillation Investigators 1996a,b) . The annual frequency of major bleeding events associated with excessive anticoagulation with warfarin ranges from 2Á0% to 3Á5% (The Atrial Fibrillation Investigators 1994; Lip et al, 2011) , with the absolute risk of thrombosis associated with overcorrection being in the same range (Hanslik & Prinseau, 2004) .
The current guidelines for treating over-anticoagulated patients advocate restoration of the INR to the target range quickly in order to prevent bleeding whilst avoiding overcorrection, which increases the patient's risk of thromboembolism. Apart from warfarin discontinuation, non-urgent correction of over-anticoagulation is achieved through oral vitamin K administration . Although oral vitamin K is effective in lowering the INR in over-anticoagulated patients (Crowther et al, 2000; Watson et al, 2001) , the currently used fixed-dose regimens do not adequately allow for differences in individual patient INR values. Whilst in excessively anticoagulated patients a particular dose may fail to sufficiently lower the INR, it can lead to over-correction in those who are only mildly overanticoagulated (Sconce & Kamali, 2006; Denas et al, 2009) .
In an earlier pilot study, we demonstrated that individualized vitamin K dosing, based upon index INR, resulted in a significantly greater proportion of over-anticoagulated patients having INR 1Á8-4Á0 at 24 h compared to data held in clinic on patients receiving a fixed-dose regimen (71% vs. 39%; P < 0Á001) (Briz et al, 2010) . The data generated from this pilot study helped us to develop a new improved individualized vitamin K dosing algorithm, based upon index INR and body surface area (BSA), which was estimated to have a greater power of accuracy in computing vitamin K dose for lowering INR to within therapeutic target range in over-anticoagulated patients than the original dosing algorithm (Briz et al, 2010) . We assessed the performance of the improved 'tailored' vitamin K dosing regimen against a fixed-dose regimen currently used in our local hospitals in the reversal of warfarin-induced over-anticoagulation in a randomized controlled clinical trial. As part of the trial we also investigated retrospectively the potential impact of patient factors, as well as genetic factors that influence warfarin pharmacology and metabolism and vitamin K disposition, on the extent of INR reversal.
Methods

Patient recruitment
This single-centre, open-label, randomized controlled study had approval by the National Research Ethics Service-Committee North East, Newcastle & North Tyneside (ref: 11/NE/ 0249). The trial was registered with the International Standard Randomised Controlled Trial Number (ISRCTN) Registry under the name 'Reversal of over-anticoagulation with vitamin K' (trial registration no: ISRCTN79841657). Over-anticoagulated patients presenting to the anticoagulant clinics at the Royal Victoria Infirmary and the Freeman Hospital, Newcastle upon Tyne were recruited into the study. Patients on warfarin therapy (irrespective of the duration) referred to our clinics with supra-therapeutic INR who were either asymptomatic or had minor bleeds, according to the classification of Fihn et al (1996) , were eligible to take part. As in our earlier pilot study, only patients with a confirmed venous INR ≥ 6Á0 were eligible, based on evidence that such patients are at significant risk of imminent harm, with a recorded risk of 8Á8% for abnormal bleeding and 4Á4% for a major bleed in the following 14 days compared to no bleeds occurring in a control population within target INR range over the same period (Hylek et al, 2000) . Patients were excluded if they met one or more of the following criteria: younger than 18 years of age, life expectancy less than 10 days, presence of major bleeding requiring immediate and complete correction of anticoagulation, a history of thromboembolic / major haemorrhagic event in the previous 3 months, known sensitivity to vitamin K, liver disease, indication for acute normalisation of INR (such as imminent surgery), scheduled discontinuation of warfarin therapy, receiving thrombolytic therapy within 48 h, a platelet count less than 50 9 10 9 /l, unable to return to the clinic the next day for laboratory/clinical assessment.
Study protocol
On presentation, after confirmation of eligibility and having obtained informed consent, 5 ml venous blood was taken from each patient and transferred into EDTA tubes for subsequent DNA extraction and genotyping for the VKORC1, CYP2C9 and CYP4F2 genes. Information on patient age, sex, body weight, height, co-morbidities and concurrent therapy was collected. Possible reasons for over-anticoagulation were ascertained (e.g. increased alcohol consumption, change in medication and change in dietary habits).
Patients were allocated using block randomisation (block size = 10) to two groups ('control' and 'tailored dose') to receive oral vitamin K 1 (phytomenadione; Konakion â , Roche, Basel, Switzerland). The control group received vitamin K 1 , either 1 or 2 mg p.o. based on index INR and bleeding risk according to the current guidelines in place in the Northern Region Hospitals for reversal of non-urgent over-anticoagulation (Hanley, 2004; Keeling et al, 2011) . The vitamin K 1 dose for those patients who were randomised to the 'tailored dose' arm was calculated in the clinic using a simple calculation generated within a Microsoft â Excel file which employed the following formula:
1Á0135 (Briz et al, 2010 Bois, 1916) .
A further venous sample for INR determination was taken at 24 (AE3) h. The INR check was performed by personnel blinded to the study treatment, thus preserving the study blindness. The individual patient's warfarin therapy was re-started 24 h after vitamin K ingestion, as instructed by the responsible physician/pharmacist, based on the DAWN AC dosing programme (Poller et al, 1998) , providing that the patient was no longer over-anticoagulated.
The need for additional doses of vitamin K at ≥24 h was considered if the patient's INR was >6Á0 outside of the study, following the local guidelines (Keeling et al, 2016) . The need for low molecular weight heparin (LMWH) administration at ≥24 h was considered if the patient's INR was sub-therapeutic and he/she was clinically adjudged to be at high risk of thrombosis. The decision for bridging with LMWH in all patients with sub-therapeutic INR results was made following an assessment of the patient's thrombotic risk according to the following clinical scenarios: (i) history of previous venous thromboembolism whilst the INR was within therapeutic range, with subsequent re-assignment to a higher target INR of 3Á5; (ii) mechanical heart valve (other than a bileaflet aortic valve) (Keeling et al, 2016) . LMWH administration was also considered if the INR value was below the lower limit of the therapeutic range by >0.2 units.
Patients were followed-up at two further clinic visits (day 7 (AE2 days) and day 14 (AE2 days)) to check for anticoagulation control and possible adverse effects of thromboembolism or haemorrhage using standard proforma of questions. Further observational information on thromboembolism/bleeding events was collected from patients' notes up The study protocol was amended later during the trial to make the visits on days 7 and 14 optional for patients in an attempt to boost recruitment. The amendment also involved inclusion of patients with repeated admissions to clinic for excessive anticoagulation. We allowed for double inclusion of patients with supra-therapeutic INR provided that there was sufficient length of time (minimum 30 days) between each episode, which would not bias the conclusions of the study.
Primary & secondary outcome measures
The primary measure was the proportion of patients reaching to within AE0Á2 units of their absolute therapeutic INR range (reported as 'within target range') 24 h after receiving oral vitamin K in the 'tailored dose' group compared to the 'control' group. An INR value of >0Á2 units below or above the individual target INR range at 24 h was considered as overand under-correction of over-anticoagulation, respectively, as these ranges (according to our local practice) are deemed to be clinically relevant, thus prompting the personnel in charge of patient anticoagulation management to consider the possible need for intervention.
Secondary measures included the need for repeated doses of vitamin K 1 , the need for heparin administration and the presence of any thromboembolic / haemorrhagic events during the study period.
Genotyping
Leucocyte DNA was extracted from blood samples according to an established in-house method (Daly et al, 1996) . Genotyping for VKORC1 (À1639G>A; rs9923231), CYP2C9 (*2 and *3 alleles; rs1799853 and rs1057910) and CYP4F2 (V433M; rs2108622) was performed using the StepOne TM Real-Time polymerase chain reaction (PCR) System with Taqman â SNP Genotyping Assays, Applied Biosystems (Foster City, CA, USA). Genotype results for all polymorphisms were validated using control samples that had been genotyped as part of a previous study (Biss et al, 2012) .
Sample size
Based on our clinic data for a 12-month period, just over 30% of non-urgent cases over-anticoagulated with warfarin achieved an INR within their target range 24 h after oral vitamin K (1 or 2 mg p.o.) administration. To detect a 20% increase (i.e. from 30% to 50%) in the proportion of over-anticoagulated patients achieving their target INR 24 h after vitamin K administration using the new tailored dosing regimen, with 80% power and at the 5% significance level, required 93 patients in each of the two study groups.
Statistical analysis
Statistical analyses were performed using Minitab 17.0 (Minitab Ltd., Coventry, UK). Data were checked for having a normal distribution. Where data were not normally distributed, logarithmic transformation was applied in order to achieve normality. Two sample t-tests were performed if approximate normality was achieved. Otherwise, MannWhitney U-tests were used. Chi-squared tests were performed for comparing categorical data across groups.
Pearson correlation test was used to evaluate relationships between variables. Stepwise regression analysis of data was used to evaluate the impact of patient characteristics and genetic polymorphism in VKORC1, CYP2C9 and CYP4F2 on INR reversal. Results are presented as mean AE standard deviation, SD (range) unless otherwise stated. A P < 0Á05 was taken as statistically significant.
Results
Between June 2012 and February 2016, 186 patients (10 repeat cases) were recruited into the study. Five patients were later withdrawn; 3 due to administrative problems associated with screening, one was lost to follow-up and one failed screening. Of the remaining 181 cases, 91 (including 2 repeat cases) were allocated to the control group and 90 (including 6 repeat cases) to the tailored dose group. The two groups were well matched with respect to demographic and clinical characteristics (Table I) . Index INR on presentation for the whole study population was 8Á0 AE 2Á0 (5Á3-21Á8). Patients included in the study had different target INR ranges based on the indication for which they were being treated with warfarin.
The possible reasons for excessive anticoagulation (if recorded) were extracted from the patients' clinical records. These included change in diet (41 patients), excessive alcohol consumption (7 patients) and change in medication (41 patients). Of the latter group of patients, 12 had stopped taking a medication and 29 had started a new medication shortly prior to the event. Of the 12 patients that had stopped taking a medication, the medication was identified as having either major (in 6 patients), moderate (in 4 patients) or minor (in 2 patients) interaction with warfarin. Of the 29 patients that had started a new medication, the medication was identified as having either major (in 6 patients), moderate (in 9 patients) or minor (in 2 patients) interaction with warfarin; in the remaining 12 patients the medication was not deemed to interact with warfarin.
In the control group, 81 patients received 1 mg of vitamin K and 9 patients received 2 mg of vitamin K, while for 1 patient the vitamin K dose administered was not recorded. The tailored dose group on average received a higher dose of vitamin K than the control group [1Á1 AE 0Á3, (1Á0-2Á0) vs. 1Á8 AE 0Á8 (0Á4-6Á0), 95% confidence interval (CI) for difference: À0Á8783, À0Á5217; t-test] (Fig 1) . Male patients required greater doses of vitamin K than their female counterparts (95% CI for difference: 0Á299-0Á933; t-test) (Fig 2) .
Primary outcome
Mean INR at 24 h was different between the two study groups [95% CI of means: (0Á1167-0Á3441; t-test) (Table II) ]. Overall, the tailored dose vitamin K regimen performed better than the fixed-dose regimen, in terms of the proportion of cases being within, above or below the target INR range at 24 h (P = 0Á002; chi-squared test) (Table III) .
A greater proportion of cases in the tailored dose group returned to within their individual target anticoagulation 24 h after vitamin K dosing compared to the control group (68Á9% vs. 52Á8%, P = 0Á026; chi-squared test) (Table III) . INR value at 24 h was above target therapeutic range in a greater proportion of cases in the control group compared to those in the tailored dose group (34Á0% vs. 12Á2%, P < 0Á001; chi-squared test). The proportion of cases with over-corrected INR was not different between the tailored dose group (18Á9%) and the fixed-dose group (13Á2%) ( Table III) 
Secondary outcomes
For a subset of cases, INR values on day 7 (71 tailored dose and 77 fixed-dose) and day 14 (63 tailored dose and 72 fixed-dose) following vitamin K administration were available. There was no difference in mean INR between both groups at either time-point (54Á5% vs. 53Á5% for day 7; 58Á3% vs. 52Á4% for day 14) (Table III) . Four cases in the control group had an INR > 6Á0 at 24 h and subsequently received an oral dose of vitamin K, according to the study protocol. Of the 4 cases, 2 received a second additional dose of vitamin K 24 and 96 h later. One case in the tailored dose group, admitted with a urinary tract infection and raised INR of 7Á5, received a second dose of vitamin K at 48 h, following a rise in INR from 5Á4 at 24 h to 6Á9 at 48 h. On day 7, two cases in the control and two in the tailored group had an INR > 6Á0 and thus received a dose of vitamin K. Similarly, on day 14, three cases in the control and two in the tailored group received a dose of vitamin K. According to the study protocol, the remaining cases with INR < 6Á0 at 24 h were deemed not to require additional dose of vitamin K. One case with INR = 6Á7 at 24 h was not deemed by the reviewing clinician to be at high risk of bleeding and hence did not receive an additional dose of vitamin K.
Twenty-nine cases (12 in the control and 17 in the tailored group) had a sub-therapeutic INR (where the INR value was below the lower limit of the therapeutic range by ≥0Á2 unit) at 24 h. LMWH was administered to only two of these subjects (one in each of the fixed-dose and tailored vitamin K dose group); both were on warfarin therapy for antiphospholipid syndrome and were deemed to be at increased risk of thrombosis. Twenty cases were administered heparin between 48 h and 16 days after vitamin K administration. However, the decision to administer heparin to these subjects was not study-related and reflected alteration of anticoagulation during admission with the use of therapeutic or prophylactic LMWH while warfarin was interrupted (Table IV) .
Vitamin K has a short half-life of 1Á5-3 h, with main effect on anticoagulation appearing within 12-24 h after its administration (Chibisov, 2007) . Therefore, events reported during the first 24-48 h after vitamin K administration were considered as being related to study intervention (i.e. either vitamin K dose was insufficient to return INR to within target range or it was in excess of that required leading to overcorrection of INR). No major bleeding events according to the International Society on Thrombosis and Haemostasis classification (Schulman & Kearon, 2005) were reported in the trial. Of the 10 minor bleeding adverse events recorded during the trial, 4 occurred in the control group and 6 in the tailored dose group (Table V) . Three of the bleeding episodes (1 in the control group and 2 in the tailored dose group) were reported within 2-7 days after the initial vitamin K dose administration. The remaining 7 minor bleeding events took place within 7-23 days following vitamin K administration (3 in the control group and 4 in the tailored dose group). All these events are in accordance with bleeding symptoms anticipated while on anticoagulation and were unrelated to the initial vitamin K dose administration. In all, one thromboembolic event in the tailored vitamin K dose group was reported 4 days after the study intervention. The recurrence of thrombosis was associated with malignancy, with the patient's INR in the therapeutic range, and was therefore unrelated to vitamin K administration (Table V) . 
Associations between genotype, patient characteristics and vitamin K dose
No differences in genotype frequency for the VKORC1 (À1639G>A; rs9923231), CYP2C9 (*2 and *3; rs1799853 and rs1057910) and CYP4F2 (V433M; rs2108622) genes were observed between the two study groups. According to stepwise regression analysis neither age, height or CYP2C9, VKORC1 and CYP4F2 genotype influenced INR at 24 h. Index INR and vitamin K dose contributed to the INR at 24 h (R 2 =24Á6%; P < 0Á001). Patient weight appeared to be a more significant predictor of INR at 24 h compared to BSA, with the latter used in the tailored dosing algorithm to calculate vitamin K dose. In contrast to the fixed-dose, the tailored vitamin K dose was influenced by both index INR and BSA, as expected (Fig 3) .
The vitamin K dose for the control group was estimated using the tailored dose equation. According to regression analysis, the difference in vitamin K dose (predicted -actual dose) was associated with BSA (R 2 =32Á7%; P < 0Á001) and index INR (R 2 =17Á8%; P < 0Á001). The predicted dose of vitamin K increased with increasing BSA and index INR (Fig 4) . The predicted vitamin K dose was higher than the actual dose administered [1Á7 (0Á1-3Á0) vs. 1Á1 (1Á0-2Á0) mg; difference in dose: 0Á6 (À1Á0 to 2Á0) mg]. For patients who had received the 1-mg vitamin K dose (n = 77) the predicted vitamin K dose was higher [1Á7 (0Á1-3Á0) mg; mean difference: 0Á7 (À0Á9 to 2Á0) mg], whilst for those who had received the 2-mg dose (n = 8) the predicted dose was slightly lower than the actual administered dose [1Á9 (1Á0-2Á7); mean difference: À0Á1 (À1Á0 to 0Á7) mg].
The study results were used to produce a new and more refined vitamin K dosing algorithm. By regressing the target INR to index INR, vitamin K dose and weight, the following vitamin K dosing equation was produced:
Vitamin K Dose = (0Á4765 9 index INRÀtarget INR + 0Á02109 9 WeightÀ0Á645)/1Á278, where vitamin K dose is in milligrams and weight in kilograms. On average, this formula predicts the same vitamin K dose for the group of patients with restored INR to within target range at 24 h (mean dose change AE SD, 0Á06 AE 0Á49; range, À1Á19 to +1Á53 mg). However, for the over-corrected group a reduced dose is predicted (mean dose change AE SD, 0Á73 AE 0Á80; range, À1Á04 to +2Á18 mg), while for the under-corrected group a small increase in predicted dose is estimated (mean dose change AE SD, À0Á07 AE 0Á49; range, À0Á91 to +0Á95 mg).
Discussion
Bleeding is one of the most serious complications associated with warfarin therapy (Palareti et al, 1996) . The risk of bleeding increases with excessive anticoagulation, which occurs in approximately 0Á2-0Á3% of outpatients receiving long-term warfarin therapy per annum (Penning-van Beest et al, 2001) .
Restoration of the INR towards the target therapeutic range in over-anticoagulated patients is the logical approach, with the choice of treatment depending upon the severity of patient symptoms and the anticipated risks. Evidence from randomized controlled trials supports the use of oral vitamin K in lowering the INR in asymptomatic or mildly bleeding patients (Crowther et al, 2000; Lubetsky et al, 2003; Ageno et al, 2005; Dezee et al, 2006) . However, there is no clear consensus about the optimal dose that should be given to patients. The majority of the reported studies have used fixed oral doses of vitamin K (ranging from 1Á0 to 5Á0 mg), based upon assigning dose according to a dichotomy of elevated INR values to reverse excessive anticoagulation, with a high percentage of patients being either under-or over-anticoagulated at 24 h after vitamin K dosing, leaving them at risk of either thromboembolism or haemorrhage, respectively (Sconce & Kamali, 2006; Denas (Hanley, 2004; Keeling et al, 2011) . A tailored approach to vitamin K dosing could ensure a more predictable reversal of over-anticoagulation. In an earlier pilot study of over-anticoagulated patients either asymptomatic or with minor bleeds (87 episodes in total), we demonstrated that an individualized vitamin K dosing regimen, whereby vitamin K dose was calculated based upon patient INR on presentation, performed better in lowering INR compared to fixed-dose vitamin K (38% vs. 21% INR within target range at 24 h) (Briz et al, 2010) . The results of the pilot study enabled us to refine the original tailored dosing algorithm. The latter can estimate vitamin K dose according to index INR, BSA and target INR. We have assessed the performance of the new dosing algorithm (measured as the proportion of patients returning to within target INR) against that of the fixed-dose regimen in a randomised parallel design study.
The present study results demonstrate that the tailored vitamin K dosing regimen is superior to the fixed-dose regimen: compared to the fixed-dose regimen, the tailored dose resulted in a greater proportion of patients returning to target INR range, whilst a smaller proportion remained above target INR range at 24 h.
Using the tailored vitamin K dosing algorithm, the patients in the control group who had received the 1-mg vitamin K dose were predicted to require a higher dose of vitamin K whilst those who had received the 2-mg dose require a slightly lower dose. However, there was a wide range in the predicted vitamin K doses for each of the fixed doses [for 1 mg dose: range 0Á1-3Á0 mg; mean difference between predicted and actual dose: 0Á7 (À0Á9 to 2Á0) mg; for 2 mg dose: range 1Á0-2Á7 mg; mean difference between predicted and actual dose: À0Á1 (À1Á0 to 0Á7) mg] which further suggests that the fixed-dose regimen is inappropriate for lowering INR in the majority of over-anticoagulated patients. Anticoagulation response to warfarin is influenced by environmental, clinical and genetic factors (Isbister et al, 2001; Sconce et al, 2005) , which could also influence vitamin K dose requirement in over-anticoagulated patients. We therefore also determined, retrospectively, whether patient age, sex, co-morbidity and genetic polymorphisms in the expression of the vitamin K epoxide reductase, the main target for warfarin (encoded by VKORC1 gene), cytochrome p450 CYP2C9, the enzyme responsible for the metabolism of S-warfarin (encoded by CYP2C9 gene) (Sconce et al, 2005; Kamali & Wynne, 2010) , and the mono-oxidase enzyme involved in vitamin K 1 metabolism (encoded by CYP4F2) (McDonald et al, 2009 ), affect vitamin K dose and the extent of INR reversal so that these can be used to further improve the vitamin K dosing algorithm as appropriate. Overcorrection of INR was more frequent in women than men (58Á6% vs. 41Á4%) although the differences were not statistically significant, probably due to the small number of patients evaluated. Female sex was found to be independently associated with overcorrection of INR, despite female subjects on average having received lower doses of vitamin K than their male counterparts. Patient factors of age and body size have previously been reported to influence vitamin K dose requirement (Hylek et al, 2001; Kelly et al, 2001 ). Whilst we found that patient weight and index INR influenced INR at 24 h and hence vitamin K dose requirement, patient age had no effect. Similar to our previous pilot study, we found that CYP2C9 and VKORC1 polymorphism made no contribution to vitamin K dose requirement, and neither did polymorphisms in CYP4F2. However, the present study was not sufficiently powered to detect the influence of genetics on vitamin K dose requirement. Therefore, it remains possible that the influence of these genes on vitamin K dose requirement will become apparent in a purposefully designed study in a larger population of patients.
There were no incidences of major bleeding requiring intervention, or thromboembolic events throughout the trial. There were 10 incidences of minor bleeding; patients in the tailored vitamin K dose group with minor bleeding complications were more likely to be taking drugs that interact with warfarin (Clopidogrel, Aspirin) or have chronic comorbidities; factors which are known to increase the risk of bleeding (Tran & Alderman, 2013) .
In conclusion, the current randomised controlled trial showed that 'tailored' vitamin K dosing regimen was superior to the fixed-dose regimen, leading to a more accurate reversal of excessive anticoagulation and a higher percentage of patients returning to within their target INR range. However, for the true clinical benefit of the tailored vitamin K dosing regimen in over-anticoagulated patients to be realised, a further larger study is required to establish its clinical utility, as well as its superiority over fixed-dose regimen in terms of its cost-effectiveness, by reducing the burden of management of patients with excessive anticoagulation through reductions in the number of repeat treatments/follow-ups, and the potential gains in patient quality of life and treatment safety in terms of reductions in the incidences of bleeding and thrombosis. recruitment of patients at each of the study sites and data handling; Lynne Robson, Philip Hope, Lester Rivett. The authors also wish to thank all patients who participated in the study.
